AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|
9.6 C
New York
Saturday, October 24, 2026

Tag: hair loss

Xtressé™ Brings Dermatologist-Led Hair Science to the Shower with New Patent-Pending X3 Peptide Shampoo & Conditioner Systems

Xtressé named as exclusive hair supplement and shampoo/conditioner partner of S.T.R.A.N.D.™ORLANDO, Fla., Oct. 15, 2026 /PRNewswire/ -- Xtressé™, the dermatologist-founded hair science company, is bringing...

Legacy Healthcare’s CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older

EPALINGES, Switzerland, Oct. 13, 2026 /PRNewswire/ -- Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U.S. Food and...

Hyundai Hope on Wheels makes $200,000 donation to bolster the fight against childhood cancer in Quebec

The Foundation CHUS Sherbrooke and the Montreal Children's Hospital Foundation received $100,000 each from the Hyundai Hope on Wheels.The grants, presented during two inspiring...

CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth

12 years of participation underscore the Group's growing presence in global cosmetics scienceSHANGHAI and PERTH, Australia, Oct. 6, 2026 /PRNewswire/ -- The 36th Congress...

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chainSite will employ more than 600 people in high-wage...

TWL Announces Expanded Online Access to GLP-1 Weight-Loss Care With Insurance and Self-Pay Options

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients
Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHair loss